Clinical Trial Update: 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases [Phase 4]

View source ↗

Summary

Phase 4 trial comparing 4-weekly versus 12-weekly administration of bone-targeted agents in patients with bone metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastasis
• Breast Cancer
• Prostate Cancer

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Breast Cancer, Prostate Cancer | Phase 4 | Status: COMPLETED